research reports and media, page-145

From an article by Tim Boreham in the Australian today.....was written a while ago obviously

Paradigm Biopharmaceuticals (PAR) $2.05
Palla’s lowly $86m market cap contrasts with what Palla’s Ritchie dubs the “hot and heavy” valuations ascribed to the medicinal cannabis sector, which is also focused on pain relief.
Another interesting comparison is the $394m market worth of Paradigm, which is seeking to repurpose an old deep-vein thrombosis drug for osteoarthritis pain.

So far the compound, renamed Zilosul, has worked wonders with the creaking knees and joints of ex-footballers including former Carlton great Greg Williams, while fellow Brownlow medallist Chris Judd and “Leaping” Leo Barry have invested in the company.
The drug is not approved and only available under a special access theme and is subject to two separate trials.
“Real world evidence” of 205 patients with knee osteoarthritis suggests pain reduction of more than 50 per cent. If approved — and it’s a big if — Zilosul would be worth billions.